How GLP-1 agonists help in type 2 diabetes
GLP-1 agonists such as semaglutide were developed for treatment of type II diabetes but have also been successful as weight-loss agents for non-diabetics. Many new agents are now… read more.
GLP-1 agonists such as semaglutide were developed for treatment of type II diabetes but have also been successful as weight-loss agents for non-diabetics. Many new agents are now… read more.
One promising approach to treating Type 1 diabetes is implanting pancreatic islet cells that can produce insulin when needed, which can free patients from giving themselves frequent insulin… read more.
Persons with an evening ‘chronotype”’ (going to bed late and waking up late), have a 19 percent increased risk of diabetes compared to those with a morning chronotype,… read more.
A simple blood test may predict the risk of progressive heart and kidney disease in people with Type 2 diabetes and kidney disease, according to new research published today in… read more.
People with type-II diabetes who drank the fermented tea drink kombucha for four weeks had lower fasting blood glucose levels compared to when they consumed a similar-tasting placebo… read more.
You might not think of diabetes when you think of muscle function. But a common diabetes drug that regulates blood sugar can also prevent muscle atrophy and muscular… read more.
Researchers report that patients have achieved significantly better glycemic control with once-weekly investigative insulin icodec than with with once-daily insulin glargine U100. The findings were reported on July… read more.
Renalytix plc announces that the FDA has granted De Novo marketing authorization for its KidneyIntelX.dkd prognostic test. This affirms KidneyIntelX as a first-in-class, artificial intelligence enabled prognostic testing… read more.
On 27th June 2023 NHS England issued a Medicine Supply Notification (MSN/2023/061) concerning GLP-1 receptor agonists (GLP-1 RAs) used for management of type 2 diabetes. This action has… read more.
Metabolic or bariatric surgery results in superior glycemic control, less medication usage and high rates of remission of Type 2 diabetes than medical or lifestyle intervention in patients… read more.
AstraZeneca’s Xigduo XR (dapagliflozin and metformin hydrochloride extended-release), a once-daily fixed-dose combination, has been approved by China’s National Medical Products Administration (NMPA) for the treatment of adults with… read more.
Zealand Pharma A/S a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced it has submitted a Marketing Authorization Application (MAA) to the European… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.